The increase in the price target from $9 to $11 by Piper Sandler, while maintaining a Neutral rating, suggests a positive outlook on the stock's value without a strong conviction towards a buy or sell action. This adjustment reflects an expectation of moderate growth or improvement in Hims & Hers Health's stock value in the short term.